Personalis, Inc. PSNL
15.95 USD +0.16 (+1.01%)
At closeNov 9, 2026, 7:23 PM EST
15.99 +0.04 +0.25%
After hours · Nov 9, 7:23 PM ET
15.80 Day range 16.00
5.04 52-week range 18.38
- YTD
- +100.38%
- 1 year
- +130.16%
News
globenewswire.com PSNL Deal Alert: Personalis $16.25 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
globenewswire.com PSNL Investigation Reminder: Personalis Shareholders Notified of Investigation into $16.25 per Share Merger – Contact BFA Law NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
benzinga.com Personalis Q3 EPS $(0.32) Misses $(0.25) Estimate, Sales $25.596M Beat $21.850M Estimate Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.25) by 28 percent. This is a 33.33 percent decrease over losses of $(0.24)…
businesswire.com Personalis Reports Third Quarter Results FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended…
globenewswire.com PSNL Investigation Reminder: Personalis $16.25 per Share Merger Triggers Investigation on Behalf of Shareholders – Contact BFA Law if You Hold Shares NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL)…
prnewswire.com PSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders…
businesswire.com PSNL Legal Notice: Personalis Shareholders are Notified to Contact BFA Law About the Ongoing Investigation into the $16.25 per Share Merger NEW YORK--(BUSINESS WIRE)---- $PSNL #BFA--Personalis Shareholders are Notified to Contact BFA Law About the Ongoing Investigation into the $16.25 per Share Merger.
benzinga.com Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop? Tempus AI, a company that Cathie Wood has invested in, will publish its financial results this week as its volatility continues.
benzinga.com Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
benzinga.com This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com What’s Going On With Tempus AI Stock on Monday? Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
benzinga.com On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order…
benzinga.com Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
benzinga.com Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 15.38 percent. This is a 30.43 percent decrease over losses of…
benzinga.com Benzinga Bulls and Bears: IBM, Super Micro, Tesla Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
benzinga.com Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holding while analysts see nearly 38% upside. Here's what the chart says.
benzinga.com Lake Street Downgrades Personalis to Hold, Announces $16.25 Price Target Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announces $16.25 price target.
benzinga.com BTIG Maintains Buy on Personalis, Raises Price Target to $16.25 BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $11 to $16.25.
benzinga.com Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
benzinga.com Tempus AI To Acquire Personalis In $1.5B Deal, Expanding Minimal Residual Disease Capabilities And Precision Medicine Platform Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growthExpands…
benzinga.com Needham Maintains Buy on Personalis, Raises Price Target to $17 Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $12 to $17.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…- benzinga.com Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and…
- benzinga.com Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $13 Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and raises the price target from $9 to $13.
benzinga.com Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive European Diagnostic Mark Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have…- benzinga.com Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD…
- benzinga.com Personalis to Present New Cancer Detection Data at Major Oncology Conference Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be…
benzinga.com US Agency Broadens Coverage Of Personalis Breast Cancer Test Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients undergoing neoadjuvant therapy.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $9 Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and lowers the price target from $10 to $9.
- benzinga.com BTIG Maintains Buy on Personalis, Lowers Price Target to $11 BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price target from $13 to $11.
benzinga.com Personalis Affirms FY2026 Sales Guidance of $78.000M-$80.000M vs $78.758M Est Personalis (NASDAQ:PSNL) affirms FY2026 sales outlook from $78.000 million-$80.000 million to $78.000 million-$80.000 million vs $78.758 million estimate.- benzinga.com Personalis Q1 EPS $(0.29) Misses $(0.27) Estimate, Sales $15.472M Beat $14.483M Estimate Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 61.11 percent decrease over losses of $(0.18)…
- benzinga.com Personalis Presents NeXT Personal ctDNA Data At AACR 2026 Showing 100% Sensitivity In Colorectal Cancer Monitoring Podium presentation on NeXT Personal monitoring neoadjuvant therapy in colorectal cancer;Real-world data from 10,000 patients reinforce industry-leading sensitivity;Data presented for a new NeXT…
- benzinga.com Personalis Showcases New Cancer Test To Track Treatment Resistance In Real Time Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal…
- benzinga.com Personalis Announces The Publication Of PREDICT-DNA Study In The Journal Of Clinical Oncology, Showing That Ultrasensitive Molecular Residual Disease Testing With Next Personal Can Perform Better Than Current Standard Approaches In Predicting Patient Outcomes Following Neoadjuvant Therapy The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading US cancer centers. The results demonstrate the ability of NeXT Personal to…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday 
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025
benzinga.com Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For May 6, 2025